Safety and tolerability of lenalidomide maintenance dosing in patients with multiple myeloma post-autologous stem cell transplant.
Abigail ShockleyJames A DavisKelly J GaffneyDeidra SmithErin WeedaHamza HashmiPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)
The higher incidence of lenalidomide dose modifications in the continuous arm suggests that a majority of patients are not able to tolerate continuous lenalidomide maintenance. A more tolerable option for maintenance may be an intermittent schedule, as reflected by the favorable safety outcomes in this group.
Keyphrases
- multiple myeloma
- newly diagnosed
- stem cells
- end stage renal disease
- stem cell transplantation
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- chronic lymphocytic leukemia
- bone marrow
- clinical trial
- type diabetes
- randomized controlled trial
- high intensity
- open label
- risk factors
- skeletal muscle
- adipose tissue
- insulin resistance
- study protocol
- placebo controlled